Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Cantor Fitzgerald boosted their FY2017 earnings per share estimates for shares of Aurinia Pharmaceuticals in a report released on Wednesday. Cantor Fitzgerald analyst E. Piros now anticipates that the biotechnology company will earn ($1.01) per share for the year, up from their previous estimate of ($1.15). Cantor Fitzgerald currently has a “Buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aurinia Pharmaceuticals’ FY2018 earnings at ($0.72) EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.10. The company had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/fy2017-eps-estimates-for-aurinia-pharmaceuticals-inc-lifted-by-cantor-fitzgerald-auph/1531097.html.

Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. HC Wainwright dropped their target price on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 18th. Finally, Vetr downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.72 target price for the company. in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $9.72.

Shares of Aurinia Pharmaceuticals (AUPH) opened at 6.06 on Monday. Aurinia Pharmaceuticals has a 52-week low of $1.88 and a 52-week high of $10.54. The stock’s market capitalization is $505.92 million. The firm has a 50-day moving average of $6.28 and a 200 day moving average of $6.37.

A number of hedge funds have recently modified their holdings of AUPH. Royal Bank of Canada increased its stake in shares of Aurinia Pharmaceuticals by 8.6% in the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 1,341 shares during the period. Jane Street Group LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter worth $155,000. Cutler Capital Management LLC bought a new stake in Aurinia Pharmaceuticals during the second quarter worth $184,000. Investment Centers of America Inc. bought a new stake in Aurinia Pharmaceuticals during the second quarter worth $184,000. Finally, Two Sigma Securities LLC bought a new stake in Aurinia Pharmaceuticals during the first quarter worth $240,000. 27.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.